The following is a summary of “Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for ...

However, there are no trials in ICAD using this combination. To facilitate the design of future ICAD trials, the CATIS-ICAD study (Combination Antithrombotic Treatment for Prevention of Recurrent ...

At 52 weeks, the mean change in the Kansas City Cardiomyopathy-Clinical Summary Score was 19.5 with tirzepatide and 12.7 with placebo (difference, 6.9; p<0.001). Drug discontinuation due to adverse ...